Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CCNK | O75909 | 3/20 | 0.50 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KDM5A | P29375 | 2/20 | 0.49 |
| ▸ | GRM5 | P41594 | 2/20 | 0.48 |
| ▸ | PDE2A | O00408 | 1/20 | 0.47 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5909284 | 1.00 | VNN1 (0.53) | VNN1ALDH1A1CCNKCDK12PDE4B | |
| SCHEMBL5909117 | 0.92 | ALDH1A1 (0.52) | VNN1ALDH1A1CCNKCDK12PDE4B | |
| SCHEMBL5748313 | 0.90 | ALDH1A1 (0.50) | VNN1ALDH1A1CCNKCDK12KMT2A | |
| SCHEMBL5747586 | 0.90 | ALDH1A1 (0.50) | VNN1ALDH1A1CCNKCDK12KMT2A | |
| SCHEMBL5746938 | 0.88 | ALDH1A1 (0.53) | VNN1ALDH1A1CCNKCDK12KMT2A | |
| SCHEMBL3867365 | 0.88 | ALDH1A1 (0.51) | VNN1ALDH1A1CCNKCDK12KMT2A | |
| SCHEMBL5746443 | 0.88 | ALDH1A1 (0.51) | VNN1ALDH1A1CCNKCDK12KMT2A | |
| SCHEMBL3862880 | 0.88 | ALDH1A1 (0.53) | VNN1ALDH1A1CCNKCDK12KMT2A | |
| SCHEMBL3856964 | 0.87 | ALDH1A1 (0.53) | VNN1ALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL5747495 | 0.87 | ALDH1A1 (0.47) | VNN1ALDH1A1CCNKCDK12KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030195195-A1 | Substituted pyridines having antiangiogenic activity | ABBOTT LABORATORIES | 2003-10-16 | — | — | US | claimed |
| US-20060030557-A1 | Substituted pyridines having antiangiogenic activity | HAVIV FORTUNA | 2006-02-09 | — | — | US | disclosed |
| EP-1494672-A1 | AMINOCARBONYL SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, PYRAZINES AND TRIAZINES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003086398-A1 | AMINOCARBONYL SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, PYRAZINES AND TRIAZINES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030195195-A1 | Substituted pyridines having antiangiogenic activity | ABBOTT LABORATORIES | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195195-A1 | Substituted pyridines having antiangiogenic activity | FLT1, FLT4, KDR | VNN1 2897/4885ALDH1A1 206/4885CCNK 99/4885 |
| US-20060030557-A1 | Substituted pyridines having antiangiogenic activity | FLT4, KDR, FLT1 | VNN1 2577/4885ALDH1A1 424/4885CCNK 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.